Dr. Feng Ren received his Ph.D. degree in chemistry from Harvard University in 2007. He then spent 11 years in the discovery and development of small molecule innovative drugs at GlaxoSmithKline (GSK), where he served as the principal scientist, program leader, director and head of chemistry of Neurodegeneration DPU, a global drug R&D unit in neurosciences in GSK. In 2018, Dr. Ren joined Medicilon, a contract research organization (CRO) providing drug discovery services to the biopharmaceutical companies globally, where he served as senior Vice President and head of the drug R&D service business of the Chemistry Department and Biology Department with over 600 chemists and biologists.

In 2021, Dr. Ren joined Insilico Medicine as CSO, responsible for internal pipelines and external collaborations in drug discovery and development. In his career Dr. Ren successfully developed multiple preclinical candidate compounds/clinical phase I compounds for the treatment of non-small cell lung cancer, multiple sclerosis, psoriasis, inflammatory bowel disease, Parkinson's disease, and neuropathic pain. Dr. Ren published over 30 peer-reviewed papers and over 20 patents.